MGG02-001.indd 1..22 :56:55 AM
1 0 2 2 29 1 2 5 1 2 GG02-00 目次その他.indd 2..22 :32:48 AM
c o n t e n t s 01 02 2 p1 p6 p p p p24 p30 p35 p39 p43 p47 p50 p54 p58 p63 p67 p71 p76 p80 p84 p87 p90 GG02-00 目次その他.indd 3..22 :32:49 AM
01 GL 7 GuidelineGuidance 1 1 2 01 02 1 75g OGTT 5364567 1 MGG02-01.indd 1.. :27:29 AM
3 4 CaseVariation 5g OGTT 2 3 HbA1c 4 IFG 2 MGG02-01.indd 2.. :27:30 AM
MethodApproach 1 75g OGTT 1 1 75g OGTT 1 HOMAIRFIRIFPG42.5 FIRI UmL 75g OGTT 900UmL 2 I. I. IRI 30IRIPG 30PG I. I. 0.4 3 600 mgdl HOMAIRHomeostasis model assessment of insulin resistance FIRI FPG IIInsulinogenic index I RI PG 2 3 HbA1c 5 3 02 01 MGG02-01.indd 3.. :27:31 AM
2 AB IFGimpaired fasting glucoseigtimpaired glucose tolerance mgdlifgigt A 5883 4 IFG 2 4 MGG02-01.indd 4.. :27:31 AM
5 5 02 01 MGG02-01.indd 5.. :27:32 AM
2 JDS ADA EASD IDF CDA mgdl 8 700 8 0 726 2 mgdl 809 0 5 900 HbA1C 6.5JDS 7.0 6.5 6.5 7.0 mmhg LDLC HDLC 0 575 0 0 0 0 0 0 30 95 80 0 70 70 95 80 40 40 45 40 46 40 TGmgdL 0 0 0 0 JDSADAEASDIDFCDA JDS0.41g 3HbA1cGA1,5AG HbA1c GA 1,5AG 35 4 1 2 EBM HbF 2 2 4 HbA1c 1 30 1 Oxyhyperglycemia 3mgdL 30 9 02 01 MGG02-02.indd 9.. :25:48 AM
5 HbA1cGAAG 3 MGG02-02.indd.. :25:49 AM
0 MethodApproach 1 2 4 5 02 01 MGG02-.indd.. :37:24 AM
1 3 1 1 DPP4 GLP1GIP SU 22 MGG02-.indd 22.. :37:25 AM
2 4 23 5 02 01 MGG02-.indd 23.. :37:25 AM
7 1 5 34 30 24 68 57 301 26 5 57 30 24 57 2.57.5375573 3755 24 5 28 MGG02-.indd 28.. :40:53 AM
2 p p 5 1 6 01 02 53 2800 2 MGG02-.indd 53.. :45: AM
3 GL 1 GuidelineGuidance 1 1 2 3 JSH0 980 89mmHg 3 1 JSH 0 980 89mmHg 3 p62 54 MGG02-.indd 54.. :47: AM
2 GL 3 GuidelineGuidance 1 2 3 4 GDM 84 7 NE JM 358 90 Diabetes Care 33676 63 02 01 MGG02-.indd 63.. :50:33 AM
2 3 4 1SU DPP4 2 3 4GI 5 6 73 02 01 MGG02-.indd 73.. :52: AM
2 GL 269 GuidelineGuidance 1 2 3 4 1 1 2 5 CDE 2p271 287 02 01 MGG02- 修正後.indd 87.. :54: AM
表紙 4.indd 2..28 :55:00 AM